A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. [electronic resource]
Producer: 20020123Description: 890-9 p. digitalISSN:- 0969-9961
- Alzheimer Disease -- blood
- Amyloid Precursor Protein Secretases
- Amyloid beta-Peptides -- analysis
- Amyloid beta-Protein Precursor -- analysis
- Animals
- Anticholesteremic Agents -- pharmacology
- Aspartic Acid Endopeptidases
- Brain Chemistry -- drug effects
- Cholesterol -- analysis
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Endopeptidases -- metabolism
- Enzyme Inhibitors -- pharmacology
- Female
- Humans
- Male
- Membrane Proteins -- analysis
- Mice
- Mice, Transgenic
- Nerve Tissue Proteins -- analysis
- Oxidoreductases -- antagonists & inhibitors
- Oxidoreductases Acting on CH-CH Group Donors
- Piperazines -- pharmacology
- Presenilin-1
- Protein Processing, Post-Translational -- drug effects
- Serum Amyloid P-Component -- analysis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.